Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2018 Oct 7;504(3):602-607. doi: 10.1016/j.bbrc.2018.04.075. Epub 2018 Apr 19.

Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications.

Author information

1
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore.
2
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Department of Pharmacology, University of British Columbia, Vancouver, BC, Canada.
3
Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, 119260, Singapore; Neurobiology and Ageing Research Programme, Life Sciences Institute, National University of Singapore, 119260, Singapore.
4
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Neurobiology and Ageing Research Programme, Life Sciences Institute, National University of Singapore, 119260, Singapore.
5
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Department of Biology, San Diego State University, San Diego, CA, USA. Electronic address: phcdrh@nus.edu.sg.

Abstract

It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is responsible for homeostatic maintenance of hundreds of distinct SL species. This pathway is perturbed in a number of pathological processes, resulting in derangement of the "sphingolipidome." Recently, advances in mass spectrometry (MS) techniques have made it possible to characterize the sphingolipidome in large-scale clinical studies, allowing for the identification of specific SL molecules that mediate pathological processes and/or may serve as biomarkers. This manuscript provides an overview of the functions of SLs, and reviews previous studies that have used MS techniques to identify changes to the sphingolipidome in non-metabolic diseases.

KEYWORDS:

Autoimmune disease; Cancer; Ceramide; Dementia; Lipidomics; Neutral sphingomyelinase 2 (nSMase2); Sphingolipid; Sphingomyelin; Sphingomyelinase; Sphingosine-1-phosphate; Stroke

PMID:
29654757
DOI:
10.1016/j.bbrc.2018.04.075
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center